Anthony Steven Durfey, DO | |
2345 Southwest Blvd, Tulsa, OK 74107-2705 | |
(918) 582-1980 | |
(918) 561-1289 |
Full Name | Anthony Steven Durfey |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 2345 Southwest Blvd, Tulsa, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609516921 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 8046 (Oklahoma) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
Anthony Steven Durfey, DO 2345 Southwest Blvd, Tulsa, OK 74107-2705 Ph: (918) 582-1980 | Anthony Steven Durfey, DO 2345 Southwest Blvd, Tulsa, OK 74107-2705 Ph: (918) 582-1980 |
News Archive
Biologists at UC San Diego have found the "missing link" in the chemical system that enables animal cells to produce ribosomes-the thousands of protein "factories" contained within each cell that manufacture all of the proteins needed to build tissue and sustain life.
Monash University researchers and staff of the Melbourne-based biotechnology company Cerylid Biosciences Ltd, have discovered and developed a new class of anti-clotting drugs that appears to be more effective than aspirin at preventing disease-causing blood clots and has fewer side effects.
The study, published in Proceedings of the National Academy of Sciences, USA, claims to have solved this scientific riddle by analysing the genomics of primitive living fishes such as sharks and lampreys and their spineless relatives, such as the sea squirts.
Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program's inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.
› Verified 7 days ago